ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

FDA Approves Sarilumab for the Treatment of Adults with Glucocorticoid-Resistant PMR

Michele B. Kaufman, PharmD, BCGP  |  March 14, 2023

Sarilumab is now FDA approved to treat adults with polymyalgia rheumatica who have had an inadequate response to glucocorticoids or who cannot tolerate a glucocorticoid taper. This new indication is based on results from the multicenter, phase 3 SAPHYR trial.

Filed under:Drug Updates Tagged with:FDA approvalglucocorticoidPolymyalgia RheumaticasarilumabU.S. Food and Drug Administration (FDA)

Conflicts of Interest in Guideline Development: What to Do When Everyone Has a Conflict

Anne R. Bass, MD  |  March 12, 2023

Avoiding real and apparent conflicts of interest is a fundamental principle of guideline development, but what should we do when every thought leader is conflicted? An example of this conundrum in rheumatology has been the ACR’s ongoing effort to establish guidelines for the management of lupus nephritis, which has been stymied by the fact that…

Filed under:Clinical Criteria/GuidelinesEthicsProfessional Topics Tagged with:Conflict of interest

ACR Image Competition 2022, Part 4

Joana Martins Martinho, MD  |  March 12, 2023

Periungual Erythema & Its Translation on Nailfold Videocapillaroscopy in a Patient with Very Early Systemic Sclerosis A 66-year-old woman presented with Raynaud’s phenomenon and periungual erythema. HEp-2 immunofluorescence assay was positive for antinuclear antibodies, showing a centromere pattern. The presence of anti-centromere antibodies was confirmed by chemiluminescent immunoassay. The patient was diagnosed with very early…

Filed under:ConditionsSystemic Sclerosis Tagged with:Image CompetitionRaynaud'ssclerosis

Case Report: Is It Cardiac Sarcoidosis or COVID-19 Myocarditis?

Simranjit Kaur, MBBS, Sirajum Munira, MD, Farooq H. Sheikh, MD, FACC, & Anjani Pillarisetty, MD, RhMSUS  |  March 12, 2023

COVID-19 causes myriad cardiac dysfunctions, ranging from mild to fulminant disease, including myocarditis, acute congestive heart failure, cardiogenic shock and sudden cardiac death.1,2 COVID-19 myocarditis can mimic cardiac sarcoidosis clinically and on cardiac imaging, which can lead to diagnostic challenges and treatment delays. We present a case of cardiac sarcoidosis with interval development of metabolic…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportCOVID-19myocarditispulmonary sarcoidosisSarcoidosis

Speak Out Rheum: Musings on Our Past & Rheumatology

David R. Mandel, MD, FACR  |  March 10, 2023

I have been reading Yuval Harari’s thought-provoking and engaging book, Sapiens: A Brief History of Humankind, about our species’ struggles and the path that led to our emergence as the predominant species. I was captivated by the drawing of the hand of one of our ancestors and mused about what that forebear was thinking as…

Filed under:OpinionSpeak Out Rheum Tagged with:HistorySpeak Out Rheumatology

Glucocorticoid Use May Result in Loss of Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  March 8, 2023

Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.

Filed under:ACR ConvergenceDrug Updates Tagged with:ACR Convergence 2022bone lossbone mineral density (BMD)fracture riskGlucocorticoidsinflammatory musculoskeletal disease

ACR Releases New Vaccination Guideline

Ruth Jessen Hickman, MD  |  March 6, 2023

The ACR recently released its first guideline focused on vaccination in adult and pediatric patients with rheumatic and musculoskeletal diseases.1 The guideline recommends modifications to certain vaccine and medication schedules to increase immunogenicity and ensure patient safety, while encouraging providers not to miss vaccination opportunities. The Need Patients with rheumatic conditions who are on immunosuppressive…

Filed under:Clinical Criteria/GuidelinesConditionsDrug Updates Tagged with:pneumococcal vaccinerecommendationsrheumatic and musculoskeletal diseasesRMDseasonal influenza vaccinationvaccinationvaccinesvaricella zoster vaccine

Cardiovascular Safety with RA Treatments

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2023

Research by Chicre et al. found that Janus kinase inhibitors may significantly increase the risk of major adverse cardiac events and all-cause death in patients with rheumatoid arthritis (RA) when compared with other RA treatments. This study highlights the need for more comparative safety studies.

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:cardiovascularcardiovascular eventJAK inhibitorJanus Kinase InhibitorsRA Resource CenterRheumatoid Arthritis (RA)TNF inhibitorsTofacitinib

Supplemental Vitamin D May Not Protect Against Fractures in Healthy Adults

Lara C. Pullen, PhD  |  March 2, 2023

Supplemental vitamin D may not significantly lower the risk of fractures in generally healthy adults compared with placebo, according to a large study by LeBoff et al.

Filed under:Conditions Tagged with:fracture riskFracturesVitamin Dvitamin D supplementationVitamin D3

What to Expect in Healthcare Policy from the 2023 State Legislative Sessions

Joseph Cantrell, JD  |  February 21, 2023

With 2023 state legislative sessions underway, early prevailing themes may forecast areas where we will see gains this year. Key issues include utilization management, copay accumulator bans, white bagging and pharmacy benefit manager reform.

Filed under:Legislation & Advocacy Tagged with:ACR advocacycopay accumulatorspharmacy benefit managers (PBMs)state legislationwhite bagging

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 328
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences